Side Effects and Safety Both AOD 9604 and Semaglutide are generally considered safe, but they have different side effect profiles: AOD 9604 : This peptide has minimal reported side effects in clinical studies, making it a safer option for individuals who are sensitive to traditional growth hormone therapy
If approved, CagriSema would become the first GLP-1 and amylin combination product to reach the market for obesity, a genuinely novel mechanism designation that Novo Nordisk regards as a meaningful point of differentiation regardless of the tirzepatide comparison
Weve built area pages for communities including Doral, Coral Gables, Kendall, Miami Beach, Aventura, Hialeah, and more see the list above though eligibility depends on clinician licensure and pharmacy shipping, not your exact address
However, long-term dietary adjustments may be necessary